COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)

Inclusion Criteria

• •For all patients:
• •A. Patient must sign an informed consent to participate in this trial
• •B. Signed consent to participate in this trial must be given not after 14 days from the first day of symptoms COVID-19 related
• •1. Patients with severity criteria must have any of the following: dyspnea and or respiratory rate \>=30 per min and or saturation \<= 93% with fraction of inspired oxygen 21% and or ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaFi )\<300 and or lung images showing worsening in 24-48 hours
• •or
• •2. Patients without severity criteria but with 2 or more factor risks:
• •A. 50 years or older
• •B. any of the following comorbidities: Diabetes Mellitus, Hypertension, Chronic Obstructive Pulmonary Disease, Chronic Kidney Failure, non-oncological related chronic immunosuppression
• •C. Total bilirubin\>1,2 mg/dl or Blood Urea Nitrogen\> 20 mg/dl or Lactate Dehydrogenase\>245 U/L
• •D. D-dimer \> 1mg/L
• •E. Neutrophils 7.3 x 10³ or greater and or Lymphocytes lesser than 0,8 x 10³ µl
• •F. C reactive protein \>9,5 mg/dl and ferritin \> 300 ug/ml
• •G. Interleukin-6 \>7 pg/mL
• •H. antineoplastic treatment such as radiotherapy- cytotoxic chemotherapy- immunotherapy- molecular therapy- oncological surgery during the last 8 weeks